Richard J. Ranieri Sells 2,993 Shares of Xencor, Inc. (NASDAQ:XNCR) Stock

Xencor, Inc. (NASDAQ:XNCR) Director Richard J. Ranieri sold 2,993 shares of Xencor stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director now owns 19,183 shares in the company, valued at approximately $176,867.26. This trade represents a 13.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Xencor Stock Performance

Shares of NASDAQ XNCR opened at $8.36 on Thursday. The firm’s fifty day moving average is $9.07 and its two-hundred day moving average is $14.83. Xencor, Inc. has a 52-week low of $7.16 and a 52-week high of $27.24. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.89 and a current ratio of 5.89. The company has a market cap of $594.98 million, a P/E ratio of -2.73 and a beta of 0.87.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). Xencor had a negative return on equity of 31.94% and a negative net margin of 181.17%. The business had revenue of $32.73 million during the quarter, compared to the consensus estimate of $23.44 million. During the same quarter last year, the firm earned ($1.11) earnings per share. The business’s quarterly revenue was up 104.6% on a year-over-year basis. As a group, analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

XNCR has been the topic of a number of analyst reports. Wall Street Zen cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. William Blair assumed coverage on shares of Xencor in a report on Monday, April 21st. They issued an “outperform” rating on the stock. Wells Fargo & Company reduced their price target on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Finally, Barclays reduced their price target on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a report on Thursday, May 8th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $28.00.

Institutional Trading of Xencor

A number of large investors have recently made changes to their positions in XNCR. Sterling Capital Management LLC increased its holdings in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,040 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Xencor during the 4th quarter valued at about $34,000. State of Wyoming bought a new position in Xencor during the 1st quarter valued at about $34,000. CWM LLC grew its holdings in Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 2,231 shares during the last quarter. Finally, AlphaQuest LLC bought a new position in Xencor during the 1st quarter valued at about $56,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.